Efficacy of Antiviral Drugs for Viral Hepatitis c in Patients with Aplastic Anemia
Keywords:
Hepatitis CAbstract
This article examines the efficacy of antiviral drugs for treating hepatitis C (HCV) in patients with aplastic anemia, a condition that complicates management due to increased infection risk and potential for hematological toxicity. Direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir demonstrate high rates of sustained virologic response with manageable safety profiles. However, careful monitoring of blood counts is essential to mitigate risks. The review highlights the promise of effective HCV treatment in this vulnerable population and calls for further research to optimize management strategies.
References
1. Chen. C. H., Lee, S. H. (2019). Aplastic Anemia: A Review of Its Management and the Role of Antiviral Therapy. *Annals of Hematology*, 98(10), 2393-2401.
2. Dore. G. J., Ward, J. W. (2016). Hepatitis C in Australia: The Case for a Public Health Approach. *Medical Journal of Australia*, 204(9), 334-338.
3. Katz. S. J., Sweeney, J. (2018). Treatment of Hepatitis C in Patients with Comorbid Conditions: A Review of the Literature. *Gastroenterology Clinics of North America*, 47(1), 43-60.
4. Kawaguchi. T., Yoshida, H. (2023). Safety and Efficacy of Sofosbuvir/Velpatasvir in Patients with Hepatitis C Virus and Aplastic Anemia. *Liver International*, 43(6), 1214-1220.
5. Kuo. T. H., Wu, H. M. (2020). Clinical Outcomes of Direct-Acting Antivirals for Hepatitis C in Patients with Compromised Bone Marrow Function. *Journal of Viral Hepatitis*, 27(5), 495-503.
6. Liu. Y., Wu. X. (2021). Efficacy of Direct-Acting Antivirals in Hepatitis C Virus Treatment Among Patients With Hematological Disorders: A Systematic Review and Meta-Analysis. *Hepatology*, 73(3), 1007-1022.
7. Martínez. A., González, C. (2020). Aplastic Anemia and Viral Hepatitis C: Therapeutic Challenges. *Clinical Infectious Diseases*, 71(2), e525-e530.
8. Matsumoto, A., Yamaguchi, Y. (2022). Direct-Acting Antivirals in the Management of Chronic Hepatitis C in Patients with Aplastic Anemia: A Retrospective Study. *Journal of Gastroenterology*, 57(1), 34-42.
9. Yamamoto. K., Saito, T. (2021). Direct-Acting Antivirals for Chronic Hepatitis C: Safety and Efficacy in Patients with Hematologic Malignancies and Aplastic Anemia. *Blood Advances*, 5(8), 1870-1879.
10. Zhang. Y., Liu, X. (2022). The Impact of Direct-Acting Antivirals on Patients with Aplastic Anemia: A Systematic Review. *Hepatitis Monthly*, 22(4), e103497.
